Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence - Wikidata - wikimedia - TriplyDB

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

http://www.wikidata.org/entity/Q33789117

about

Oligometastatic prostate cancer: Metastases-directed therapy?The Utility of Molecular Imaging in Prostate Cancer A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)Palliative radiotherapy with or without additional care by a multidisciplinary palliative care team in patients with newly diagnosed cancer: a retrospective matched pairs comparison.Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer.The biology and treatment of oligometastatic cancer.Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)[(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results.Radiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer: A Retrospective Study Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach.The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory.Clinical variability and molecular heterogeneity in prostate cancer.Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations.Stereotactic ablative body radiotherapy (SAbR) for oligometastatic cancer.The Role of Hypofractionated Radiotherapy in Prostate Cancer.Spanish Society of Radiation Oncology clinical guidelines for stereotactic body radiation therapy in lymph node oligometastases.The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.Salvage pelvic lymph node dissection in recurrent prostate cancer: surgical and early oncological outcome.Complete PSA Response Following Stereotactic Ablative Radiotherapy for a Bony Metastasis in the Setting of Castrate-Resistant Prostate Cancer.(99m)Tc-HDP bone scintigraphy and (18)F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer.What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study.Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.(68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapy.Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience.Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy.Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report.Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review.Stereotactic ablative body radiotherapy in patients with prostate cancer Emerging role of cytoreductive prostatectomy in patients with metastatic disease Worth a local treatment? - Analysis of modern radiotherapy concepts for oligometastatic prostate cancer A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial)The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer

P2860

Q26740069-9441A844-B124-4845-BC35-F095525B481B Q26764746-A70CD591-DDF7-453C-9F56-2587849AF4A5 Q27000180-64F6D8AA-06A9-4D4B-99D5-B62886B6F49B Q32173730-F83149DB-0A1D-41BF-BE97-4203D3D00676 Q35164910-1C581153-6156-47E2-8C9B-1709204DCCE7 Q35253783-B2CCA4C2-9FD3-4591-983E-6638FFEF2E67 Q35569482-2DDD5152-63EC-4E66-A3EA-D4FFABBCA7B3 Q35832153-20BAD3DB-9206-4D28-A56F-847E8E7D4122 Q36377961-D4D5F14F-6600-476A-8A7B-6366C694F20B Q36489655-A1D56B31-6340-4411-A874-78688342EEBC Q36581142-757E7A1D-F27F-4606-8102-61B88614405E Q37187233-944E7D3C-1710-4B01-867F-1587A228BE00 Q38648799-7F20468D-A309-479A-9363-46760EDBB262 Q38808811-42BA074D-817A-4ABE-A081-8B313FE058EF Q38821599-5A7F314A-97D3-452D-86B4-31637B0BF592 Q38977428-576E858E-C471-4A15-A16D-E515C86C4A85 Q39051290-1C59B068-8082-4EDA-8918-7BD6778BB3C1 Q39200876-7A12F2CD-968F-4690-89F5-3EAAC2C7BBE2 Q40585481-5B662055-20FF-4414-8983-702C47201BDE Q41566002-E052393B-B0F5-4DDF-BC2C-F75D67D724F8 Q42785526-64B89657-AC8C-4A84-B5BB-3328DF505485 Q43156072-4F9C9041-7906-4627-97CB-E7B49AF43588 Q46780712-BC423B5F-ADC4-46AB-BB14-AF2F4A041C9B Q47904167-97898604-2504-4516-AE44-A6EE992319DC Q50099352-1C1938C6-93E8-4934-9947-BC5C29E4C07D Q51031963-0A53CB44-05CD-472F-9875-C2A70A1C4EFC Q51715242-C9C863AA-F778-4481-A5A9-DBEED34DE845 Q53093291-28399211-8C8D-4725-977A-9918742E233D Q53267613-D7A0C348-484A-4B9C-B930-E6D19123B4B7 Q53414816-DA4FDD57-0EBC-49F9-BDFE-D185747663B6 Q55379783-56351807-2EF9-44C4-93BE-CF3ED705ED23 Q57112486-EEC9B56D-6A52-48CC-9A8F-9E27B50A4A96 Q58562228-93534412-F3BC-4D7F-9ACF-7DEB564D224C Q58706995-1270F420-BA74-4F87-8F0E-78148306BFD3 Q58736621-1EF0BC16-608E-4A2A-B2BF-62A4821723CE Q58802712-A9BC05A2-61FE-436C-AA60-F86BA56A8C68

P2860

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

http://www.wikidata.org/entity/Q33789117

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

@ast

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

@en

type

label

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

@ast

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

@en

prefLabel

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

@ast

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

@en

P1433

Q33789117-C9AF5A15-91DE-4F40-8EB3-088D7BB93989

P1476

Q33789117-98C7A7F3-28B8-40AD-826C-5C2127CD1385

P2093

Q33789117-276DA89C-CEA7-4E2E-8CB7-6B0EC2F43537

Q33789117-3F1A695F-E1D3-4E94-8C86-210AF5ECA894

Q33789117-5DF5C131-C462-43F1-935F-F415E4695938

Q33789117-6F0F2CBA-58F6-469E-A6D1-5F54AB641871

Q33789117-8B70202F-2CE5-428B-A476-02F195264D8B

Q33789117-B2D7F869-3613-49F3-8F5F-64D06AF89019

Q33789117-BD493DF9-E397-45B1-8BA4-67B3157B25A7

Q33789117-D33F500A-8837-4F86-BCAC-9C7808199956

Q33789117-EAB8F760-4621-4D66-B317-DB3258B5032F

Q33789117-F439CFA7-E7BC-4C4A-B449-DBFC0247EE54

P2860

Q33789117-08E0893B-6E08-43D0-AFE4-CED1A75840B7

Q33789117-0D95B2B6-5ABD-4DA0-9E3B-95D690C97B55

Q33789117-0DE5BE21-EE21-4AEB-B5B8-0F3D929E257D

Q33789117-12DF1BB3-2B7D-4F20-A05B-837F8086F304

Q33789117-137ECB40-5B71-4825-ABFC-AAD17C6DAC53

Q33789117-18C20F5E-0791-4F30-97D8-54228467F5E0

Q33789117-1C46DACC-1C44-46F7-B72F-1750680410CF

Q33789117-1DFA5E19-EBDC-44B9-8060-8EDEF75974A7

Q33789117-1E9989AE-0AFB-46E8-A5BC-79EFCFF50CEF

Q33789117-27D34C01-8CAD-47AB-9B79-BCF1D4FD3989

P2888

Q33789117-B6031929-C742-44CB-A5ED-89AD5A80DA82

P304

Q33789117-DEBE54D0-0D33-4735-86BA-913359FA9942

P31

Q33789117-153F5E39-D903-4300-B39E-FF6D4759C469

P356

Q33789117-EE22553C-102D-407F-8360-78CB4F6B7959

P478

Q33789117-49A76979-7ED7-4E8D-BBD1-76A5107A96F8

P577

Q33789117-05724C22-1A1A-44FA-9FAD-C593C2BFAB7F

P5875

Q33789117-E8680575-BCDC-4D28-9EB5-8E09575268D2

P6179

Q33789117-1E241144-9C39-41A9-834C-5CFBA625123D

P698

Q33789117-6A765CB9-6D82-4C0B-BA15-04EF7AFBCFE3

P921

Q33789117-35ABFC4A-C052-4F7D-A732-A93AD3B60160

P932

Q33789117-D4F1B3D5-4D55-4A0C-82BD-CF7B93D9178C

P356

1748-717X-9-135

P1433

Radiation Oncology

P1476

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

@en

P2093

Arne Hautekiet

http://www.w3.org/2001/XMLSchema#string

Bieke Lambert

http://www.w3.org/2001/XMLSchema#string

Filip De Vos

http://www.w3.org/2001/XMLSchema#string

Gaethan Maes

http://www.w3.org/2001/XMLSchema#string

Gert De Meerleer

http://www.w3.org/2001/XMLSchema#string

Karel Decaestecker

http://www.w3.org/2001/XMLSchema#string

Louke Delrue

http://www.w3.org/2001/XMLSchema#string

Piet Ost

http://www.w3.org/2001/XMLSchema#string

Tom Claeys

http://www.w3.org/2001/XMLSchema#string

Valérie Fonteyne

http://www.w3.org/2001/XMLSchema#string

P2860

ESUR prostate MR guidelines 2012

The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?

Stereotactic body radiation therapy: the report of AAPM Task Group 101.

Stereotactic body radiotherapy for oligometastases.

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer.

The natural history of noncastrate metastatic prostate cancer after radical prostatectomy

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.

Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.

P2888

1748-717x-9-135

P304

135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1748-717X-9-135

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263054768

http://www.w3.org/2001/XMLSchema#string

P6179

1006075146

http://www.w3.org/2001/XMLSchema#string

P698

24920079

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

4066290

http://www.w3.org/2001/XMLSchema#string